BioInvent International AB (publ) (STO:BINV)
Sweden · Delayed Price · Currency is SEK | Market Cap | 278.35M -86.4% |
| Revenue (ttm) | 39.98M -83.7% |
| Net Income | -486.85M |
| EPS | -7.40 |
| Shares Out | 65.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,584,404 |
| Open | 5.100 |
| Previous Close | 5.430 |
| Day's Range | 4.100 - 5.100 |
| 52-Week Range | 4.135 - 34.850 |
| Beta | 0.10 |
| Analysts | Strong Buy |
| Price Target | 76.30 (+1,703.78%) |
| Earnings Date | Oct 29, 2026 |
About STO:BINV
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin’s lymphoma, and solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to t... [Read more]
Financial Performance
In 2025, STO:BINV's revenue was 226.50 million, an increase of 406.86% compared to the previous year's 44.69 million. Losses were -332.86 million, -22.48% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for BINV stock is "Strong Buy." The 12-month stock price target is kr 76.30, which is an increase of 1,703.78% from the latest price.
News
BioInvent International AB Earnings Call Transcript: Q3 2026
Q3 results reflected lower 9M sales after a prior-year $20m mezagitamab rights payment, while costs fell and liquid funds were SEK 225m. A proposed SEK 430m rights issue prioritizes BI-1808, with initial Part C data expected in H2 2027.
BioInvent International AB Quarterly report: Q3 2026
BioInvent International AB has published its Q3 2026 quarterly earnings report on October 29, 2026.
BioInvent International AB Slides: Q3 2026
BioInvent International AB has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
BioInvent's BI-1808 and KEYTRUDA(R) Induce Durable Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer
BioInvent International (STO:BINV) - Updated efficacy data in 34 evaluable patients with a chemotherapy-free regimen; randomized Part C will add BI-1808 to the new standard of care.
BioInvent International AB Slides: Corporate presentation
BioInvent International AB has posted slides in relation to its latest quarterly earnings report, which was published on October 21, 2026.
BioInvent To Present BI-1808 Data in Platinum-Resistant Recurrent Ovarian Cancer at ESMO 2026
BioInvent International (STO:BINV) - Poster with the title "From Modest to Meaningful: Targeting TNFR2 with BI-1808 to Unlock Checkpoint Inhibitor Efficacy in Platinum-Resistant Recurrent Ovarian Canc...
BioInvent Announces Publication of First-in-Human BI-1808 Data in Clinical Cancer Research
BI-1808 monotherapy demonstrated an excellent safety profile and evidence of single-agent anti-tumor activity, correlating with tumor-infiltrating CD8+ T cells and inducing antitumor immunity. Transla...
BioInvent International AB Announces that its CFO will Retire in 2027
LUND, SE / ACCESS Newswire / October 12, 2026 / BioInvent International AB ("BioInvent") (STO:BINV) , a leader in the discovery of novel immunomodulatory antibodies, today announced that the company's...
BioInvent International AB Transcript: Investing in Life Science 2026
Immunomodulatory antibody BI-1808 recruits CD8-positive T cells into cold tumors, showing strong preclinical and early clinical efficacy, especially in ovarian cancer. Combination with PD-1 inhibitors significantly improves response rates and progression-free survival.
BioInvent International AB Slides: Corporate presentation
BioInvent International AB has posted slides in relation to its latest quarterly earnings report, which was published on September 3, 2026.
BioInvent International AB Quarterly report: Q2 2026
BioInvent International AB has published its Q2 2026 quarterly earnings report on August 27, 2026.
BioInvent International: BioInvent Announces Publication of Preclinical Manuscript on BI-1808 and BI-1910 in Cancer Research
Preclinical manuscript that characterizes the mechanism of action, broad antitumor efficacy, and immune-activating properties of BI-1808 and BI-1910 across diverse tumor microenvironmentsData demon...
BioInvent Announces Publication of Preclinical Manuscript on BI-1808 and BI-1910 in Cancer Research
Preclinical manuscript that characterizes the mechanism of action, broad antitumor efficacy, and immune-activating properties of BI-1808 and BI-1910 across diverse tumor microenvironments Data demonst...
BioInvent International: BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer
FDA Fast Track Designation granted for BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of ovarian cancer.BI-1808 in combination with pembrolizumab demonstrated a 24% confirmed ORR ...
BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer
FDA Fast Track Designation granted for BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of ovarian cancer. BI-1808 in combination with pembrolizumab demonstrated a 24% confirmed ORR an...
BioInvent International: BioInvent Publication in JECCR: Tailored Fc?R Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models
LUND, SE / ACCESS Newswire / July 28, 2026 / BioInvent International (STO:BINV)Preclinical proof-of-concept data support two distinct Fc?R-blockade strategies to enhance cancer antibody therapies a...
BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models
LUND, SE / ACCESS Newswire / July 28, 2026 / BioInvent International (STO:BINV) Preclinical proof-of-concept data support two distinct FcγR-blockade strategies to enhance cancer antibody therapies and...
BioInvent International: BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026
LUND, SE / ACCESS Newswire / July 17, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that ...
BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026
LUND, SE / ACCESS Newswire / July 17, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that its...
BioInvent International AB Slides: Corporate presentation
BioInvent International AB has posted slides in relation to its latest quarterly earnings report, which was published on June 18, 2026.
BioInvent International AB Transcript: KOL event
Key opinion leaders highlighted the strong efficacy and safety of BI-1206 and BI-1808 in lymphoma and CTCL, emphasizing their differentiated mechanisms and commercial potential. Both assets are advancing toward pivotal studies, with safety and convenience seen as major advantages for broad patient adoption.
BioInvent International AB Press release: KOL event
BioInvent International AB issued a press release on June 11, 2026, disclosing material business information to investors.
BioInvent International AB Slides: KOL event
BioInvent International AB has posted slides in relation to its latest quarterly earnings report, which was published on June 11, 2026.
BioInvent International AB Transcript: Aktiedagarna 2026
Focus is on advancing two immuno-oncology programs, with BI-1808 in ovarian cancer showing strong efficacy and safety, and BI-1206 positioned for partnering. Financial strategy centers on partnerships and royalty monetization, with a cash runway into Q1 next year. Key milestones and pivotal study readiness are expected in the next 12–24 months.
BioInvent International AB Transcript: Jefferies Global Healthcare Conference 2026
Two first-in-class immuno-oncology programs showed strong efficacy and safety in ovarian cancer, T-cell lymphoma, and non-Hodgkin lymphoma, with pivotal studies and regulatory filings planned. Key data updates and comparative studies are expected in the coming year.